Effect of Continuous Glucose Monitor (CGM) Access Expansion on Uptake Among Patients on Medicaid With Diabetes
Authors' conclusion
CGM uptake disparities can largely be overcome by eliminating CGM cost barriers. CGM use was associated with improved HbA1c across all major racial/ethnic groups, highlighting broad CGM appeal, utilization, and effectiveness across an underprivileged patient population.
Study context
- Population
- Adults with diabetes enrolled in a U.S. Medicaid program that fully subsidized CGM
- Participants
- 3,036 adults
- Exposure
- CGM uptake and HbA1c under full CGM subsidy; T1D vs T2D, racial/ethnic groups, higher vs lower fill adherence
- Outcome
- CGM fill adherence (medication possession ratio (MPR))
Main finding
As reported in the abstract
Type 1 diabetes
0.78
mean
Type 2 diabetes
0.72
mean
P = 0.06
Observational data: associations, not effects.
Further findings
HbA1c change with CGM use, T2D · pre- vs post-CGM use
- HbA1c change, T2D (P < 0.001); comparable between major racial/ethnic groups
- −1.2% [13.1 mmol/mol]
- HbA1c change, higher fill adherence (P < 0.001)
- −1.4% [15.3 mmol/mol]
- HbA1c change, lower fill adherence (P < 0.001)
- −1.0% [10.9 mmol/mol]
Original publication
Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes. Diabetes Care. Published 8 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →